FindTrial
Sign In

[203Pb]VMT-α-NET

DRUG2 trials

Sponsors

Yusuf Menda, Perspective Therapeutics

Conditions

Bronchial Neuroendocrine TumorGastroenteropancreatic Neuroendocrine TumorMeningiomaNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumor MetastaticNeuroendocrine Tumors UnresectableParaganglioma

Early Phase 1

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
Active, not recruitingNCT05111509
Yusuf MendaNeuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2
Start: 2022-08-22End: 2026-06-30Target: 20Updated: 2025-07-14

Phase 1

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
RecruitingNCT05636618
Perspective TherapeuticsBronchial Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor, Meningioma +4
Start: 2023-09-27End: 2029-12-26Target: 300Updated: 2026-05-14

Related Papers

Abstract CT088: [212Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and preliminary efficacy results from dose-finding cohorts 1,2 and 3
Cancer Research2026-04-17
Safety and preliminary efficacy results of [ <sup>212</sup> Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).
Journal of Clinical Oncology2026-01-10
Abstract C095: [212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs)
Molecular Cancer Therapeutics2025-10-22
[ <sup>212</sup> Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.
Journal of Clinical Oncology2025-05-282 citations
Interim safety and efficacy data of [ <sup>212</sup> Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs).
Journal of Clinical Oncology2025-01-272 citations